Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
Status:
Completed
Trial end date:
2020-05-04
Target enrollment:
Participant gender:
Summary
RATIONALE: Vorinostat may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth. Lenalidomide may stop the growth of multiple myeloma by blocking
blood flow to the cancer. Giving vorinostat together with lenalidomide may kill more cancer
cells.
PURPOSE: This phase I trial is studying the side effects and best dose of vorinostat when
given together with lenalidomide after autologous stem cell transplant in treating patients
with multiple myeloma.